Call Today for a FREE Confidential Case Review - Toll-Free 24/7 (866) 920-0753

Jentadueto Lawsuit

Jentadueto Lawsuit

Jentadueto contains linagliptin, a new type-2 diabetes medication that forces the pancreas to make more insulin. Some experts warn that it could overstimulate the pancreas and cause inflammation or chronic pancreatitis. The FDA is also investigating the risk of pancreatic cancer.

What You Can Do & How We Can Help

The Schmidt Firm, PLLC is currently accepting Jentadueto induced injury cases in all 50 states. If you or somebody you know was diagnosed with pancreatic cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call us toll-free 24 hours a day at (866) 920-0753.

FDA Investigates Jentadueto and Pancreatic Cancer

March 14, 2013 — The FDA has warned that all drugs in the incretin mimetic class, including Jentadueto, have been linked to a potential risk of pancreatitis (pancreas inflammation) and pancreatic cancer in a new study. Although it is still to early to tell whether Jentadueto causes pancreatic cancer, the FDA issued this Safety Communication to announce they will investigate the risk. Click here to read more.

What is Jentadueto?

Jentadueto (linagliptin / metformin) is a twice-daily pill that is prescribed to help people with type-2 diabetes control their blood-sugar levels. It was developed by the drug-company Boehringer Ingelheim and approved by the FDA in January 2012.

The problem with type-2 diabetes is that patients suffer from chronic high blood-sugar due to cellular insulin resistance. The linagliptin in Jentadueto treats diabetes by mimicking hormones that lower blood-sugar levels, similar to other drugs in the incretin mimetic class of drugs. Jentadueto also contains metformin, a diabetes drug that has been on the market for decades.

What is the problem with Jentadueto?

The problem with Jentadueto is that it contains a new drug called linagliptin, which has only been on the market since 2012. Linagliptin belongs to a class of drugs called “incretin mimetics,” which were introduced in 2006. Therefore, long-term side effects of Jentadueto and similar diabetes drugs are not fully understood.

There is a growing amount of evidence linking Jentadueto and similar drugs to pancreatitis (inflammation in the pancreas that can be chronic or acute), pancreatic cancer, and thyroid cancer. Our Jentadueto lawyers are concerned that the warnings on Jentadueto are not adequate to fully inform patients about the potential risk of cancer.

FDA Investigates Study Linking Jentadueto and Pancreatic Cancer

One of the most concerning studies regarding the link between Jentadueto and pancreatic cancer was published in the journal Diabetes in March 2013.

Over the last few years, there has been growing concern about pancreatitis and pancreatic cancer from diabetes drugs. Researchers decided to examine pancreases from deceased patients who were using an incretin mimetic drug and compare the pancreases to non-diabetics and diabetics who were using other drugs.

The researchers found evidence of pre-cancerous cellular growth. Jentadueto and other incretin mimetic drugs treat diabetes by stimulating the growth of beta-cells (which produce insulin) inside the pancreas. Not surprisingly, the pancreases of the incretin mimetic group were 40% more massive than normal.

Unfortunately, researchers also found that these cells were “eccentric” and potentially pre-cancerous. They found evidence of adenomas, which are small, benign tumors that normally must be removed because they can become malignant and cause deadly pancreatic cancer. These tumors were located in the pancreatic duct, which is where pancreatic cancer is most likely to occur. According to the researchers, even benign adenomas are concerning because patients who have surgery to remove their pancreas suffer from lifelong complications.

Jentadueto Class Action

The Schmidt Firm, PLLC is nationally recognized as a class action law firm, but we are not filing a Jentadueto class action against Boehringer Ingelheim or Eli Lilly & Co. Instead, we are filing individual lawsuits on behalf of people who were seriously injured or needed surgery after developing pancreatic side effects.

As of January 2016, over 750 lawsuits involving pancreatic side effects of incretin diabetes drugs were centralized in a Multi-District Litigation (MDL No. 2452) in the U.S. District Court for the Southern District of California, In Re: Incretin Mimetics Products Liability Litigation.

Do I have a Jentadueto Lawsuit?

The Schmidt Firm, PLLC is currently accepting Jentadueto induced injury cases in all 50 states. If you or somebody you know was diagnosed with pancreatic cancer, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call us toll-free 24 hours a day at (866) 920-0753.

Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.

Free Case Evaluation

The Schmidt Firm, PLLC has been recognized as one of the nation’s leading plaintiff’s law firms and handles cases in all 50 states. We are very proud of our legal achievements, but equally self-respecting of our firms reputation for providing personal attention to each and every client we represent.

No matter what type of case you have, you may contact us with confidence by filling out the email contact form below or calling us directly by dialing toll free 24 hrs/day (866) 920-0753.

*
*
*